Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-09
2008-09-09
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000
Reexamination Certificate
active
10518725
ABSTRACT:
Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N═ atom or a —C(Rb)═ group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH═ group; n is zero or the integer 1; Alk1is an optionally substituted aliphatic or heteroaliphatic chain L1is a covalent bond or a linker atom or group; Cy1is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
REFERENCES:
patent: 6180792 (2001-01-01), Furuya et al.
patent: 6964956 (2005-11-01), Cywin et al.
patent: 6974870 (2005-12-01), Cywin et al.
patent: 6977266 (2005-12-01), Tada et al.
patent: WO99/64400 (1999-12-01), None
patent: WO03/033502 (2003-04-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface pp. 1-15, p. 41.
“Isopentyl Nitrite” Encyclopedia of Reagents for Organic Synthesis online “http://www.mrw.interscience.wiley.com/eros/articles/ri074/sect0-fs.html” Nov. 27, 2007.
Michelotti et. al. “Two classes of p38a MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes” Bioorganic & Medicinal Chemistry Letters 2005, 15, 5274-5279.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Adams, J.L., et al., “p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines,”Process in Medicinal Chem., King, F.D., et al. (Eds.),Elsevier Science, 2001, 38, 1-60.
Adhikari, R., et al., “An adventitious synthesis of 2,2′-dipyrryl disulfides,”Aust. J. Chem., 1999, 52, 63-67.
Allen, M., et al., “Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells,”J. Exp. Med., 2000, 191(5), 859-869.
Badger, A.M., et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function,”J. Pharm. Exp. Ther., 1996, 279(3), 1453-1461.
Chan, D.T., et al., “New N- and O-arylations with phenylboronic acids and cupric acetate,”Tet. Letts., 1998, 39, 2933-2936.
Cohen, P., “The search for physiological substrates of MAP and SAP kinases in mammalian cells,”Trends Cell Biol., 1997, 7, 353-361.
Dinarello, C.A.J., “An update on human interleukin-1: from molecular biology to clinical relevance,”J. of Clinical Immunology, 1985, 5(5), 287-297.
Doza, Y.N., et al., “Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues and phosphorylated in chemically stressed KB cells,”FEBS Letts., 1995, 364, 223-228.
Enslen, H., et al., “Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6,”J. of Biol. Chem., 1998, 273(3), 1741-1748.
Griswold, D.E., et al., “Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase,”Pharmacol. Comm., 1996, 7, 323-329.
Hale, K.K., et al., “Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages,”J. of Immun., 1999, 162, 4246-4252.
Hartwig, J.F., et al., “Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: scope and mechanism,”Angew. Chem. In. Ed. Engl., 1998, 37, 2046-2067.
Hedayatullah, M., “Alkylation des pyrimidines en catalyse par transfert de phase,”J. Heterocyclic Chem., 1981, 18, 339-342 (English summary on p. 342).
Hunter, T., et al. (Eds), “Protein kinase classification,”Methods in Enzymology, Academic Press, San Diego, 1991, vol. 200, 3-39.
Jiang, Y., et al., “Characterization of the structure and function of a new mitogen-activated protein kinase (p38β),”J. of Biological Chem., 1996, 271(30), 17920-17926.
Konno, K., et al., “Improved procedures for preparation of 2-pyridones and 2-hydroxymethylpyridines from pyridine N-oxides,”Heterocycles, 1986, 24(8), 2169-2172.
Kotlyarov, A., et al., “MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis,”Nature Cell Biol., 1999, 1, 94-97.
Lam, P.Y.S., et al., “Copper-catalyzed general C-N and C-O bond cross-coupling with arylboronic acid,”Tet. Letts., 2001, 42, 3415-3418.
Lee, J.C., et al., “Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors,”Annals N.Y. Acad. Sci., 1993, 696, 149-170.
Lee, J.C., et al., “Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002,”Int. J. Immunopharm., 1988, 10(7), 835-843.
Lee, J.C., et al., “A protein kinase involved in the regulation of inflammatory cytokine biosynthesis,”Nature(London), 1994, 372, 739-747.
Luker, T.J., et al., “Palladium catalysed amination of electron deficient halothiophenes,”Tetrah. Letts., 2000, 41, 7731-7735.
McDonnell, P.C., et al., “Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6p21.3/21.2,”Genomics, 1995, 29, 301-302.
Santilli, A.R., et al., “Theino[2,3-d] pyrimidines. 1. A new method for the preparation of esters and amides of thieno[2,3-d] pyrimidine-6-carboxylic acids,”J. Heterocycl. Chem., 1971, 8, 445-453.
Sont, J.K., et al., “Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue,”Am. J. Respir Crit. Care Med., 2003, 167, 1496-1503.
Subauste, M.C., et al., “Infection of a human respiratory epithelial cell line with rhinovirus,”J. Clin. Invest., 1995, 96, 549-557.
Takekawa, M., et al., “A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK,”Cell, 1998, 95, 521-530.
Teran, L.M., et al., “Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma,”Am. J. Respir. Crit. Care Med., 1997, 155, 1362-1366.
Turner, R.B., et al., “Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds,”Clin. Infec. Dis., 1997, 26, 840-846.
Wolf, J.P., et al., “Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides,”J. Org. Chem., 2000, 65, 1144-1157.
Zhu, Z., et al., “Rhinovirus stimulation of interleukin-6 in vivo and in vitro,”J. Clin. Invest., 1996, 97(2), 421-430.
Henry, J.R. et al., “Potent Inhibitors of the Map Kinase p38”, Bioorganice & Medicinal Chemistry Letters, vol. 8, No. 23, Dec. 1, 1998, pp. 3335-3340.
International Search Report PCT/GB03/02667, dated Sep. 24, 2003.
Brookings Daniel Christopher
Davis Jeremy Martin
Langham Barry John
Celltech R&D Limited
Desai Rita
McDonnell Boehnen & Hulbert & Berghoff LLP
O'Dell David K
LandOfFree
Arylamine substituted bicyclic heteroaromatic compounds as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylamine substituted bicyclic heteroaromatic compounds as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylamine substituted bicyclic heteroaromatic compounds as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3945329